Pharma Radar

Tracking what matters in HEOR, market access, and pharma consulting for your career success

NEWEST

The Skill That Matters More Than Expertise: What a Pharma VP Learned in 25 Years

Feb 17, 2026

•

8 min read

Market Access

The UK's Innovation Dilemma: Is Britain Pricing Itself Out of the Medicine Market?

Feb 16, 2026

•

6 min read

Patient-Reported Outcomes (PRO)

The Patient Voice is Still Underused

Feb 9, 2026

•

4 min read

Pharmaceutical Policy

Why Karl Claxton Warned Against the NICE Threshold Change (And Why It Happened Anyway)

Feb 8, 2026

•

7 min read

Systematic Literature Review

Responsibility, Risk, and the Future of Evidence

Feb 7, 2026

•

4 min read

Drug Regulation

Rethinking Medicines, Evidence & Power

Feb 6, 2026

•

4 min read

ALL POSTS

Explore our archive of posts.

Outcomes Research

Drug Pricing

Real-World Evidence

Pharmaceutical Policy

Health Economics

Evidence-Based Medicine

Drug Regulation

NICE

Pharma Consulting

Systematic Literature Review

Patient-Reported Outcomes (PRO)

Tools & Productivity

Market Access

Clinical Outcome Assessments (COA)

The Skill That Matters More Than Expertise: What a Pharma VP Learned in 25 Years

A Conversation with Peter Wickersham, Vice President & General Manager of a Major UK Pharma Affiliate

Feb 17, 2026

•

8 min read

The UK's Innovation Dilemma: Is Britain Pricing Itself Out of the Medicine Market?

The UK spends significantly less of its health budget on branded medicines than comparable nations. Termination rates in the appraisal process have doubled. And companies are increasingly choosing not to launch here at all. A conversation with the ABPI's Jack Neill-Hall about what's at stake—and where the opportunity lies.

Feb 16, 2026

•

6 min read

The Patient Voice is Still Underused

Bridging the Gap Between Endpoints, HTA, and Lived Experience

Feb 9, 2026

•

4 min read

Why Karl Claxton Warned Against the NICE Threshold Change (And Why It Happened Anyway)

The Warning That Went Unheeded

Feb 8, 2026

•

7 min read

Responsibility, Risk, and the Future of Evidence

What building a HEOR consultancy during COVID reveals about leadership, judgment, and where our field is heading

Feb 7, 2026

•

4 min read

Rethinking Medicines, Evidence & Power

Lessons from My Conversation with Prof. Jerry Avorn

Feb 6, 2026

•

4 min read

Pharma Radar

The Skill That Matters More Than Expertise: What a Pharma VP Learned in 25 Years

The UK's Innovation Dilemma: Is Britain Pricing Itself Out of the Medicine Market?

The Patient Voice is Still Underused

Why Karl Claxton Warned Against the NICE Threshold Change (And Why It Happened Anyway)

Responsibility, Risk, and the Future of Evidence

Rethinking Medicines, Evidence & Power

Outcomes Research

Drug Pricing

Real-World Evidence

Pharmaceutical Policy

Health Economics

Evidence-Based Medicine

Drug Regulation

NICE

Pharma Consulting

Systematic Literature Review

Patient-Reported Outcomes (PRO)

Tools & Productivity

Market Access

Clinical Outcome Assessments (COA)

The Skill That Matters More Than Expertise: What a Pharma VP Learned in 25 Years

The UK's Innovation Dilemma: Is Britain Pricing Itself Out of the Medicine Market?

The Patient Voice is Still Underused

Why Karl Claxton Warned Against the NICE Threshold Change (And Why It Happened Anyway)

Responsibility, Risk, and the Future of Evidence

Rethinking Medicines, Evidence & Power

The HEOR Intel You Actually Need

Tracking what matters in HEOR, market access, and pharma consulting for your career success